Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a

Journal of Immunology

Volumn 180, Issue 9, 2008, Pages 6064-6069

  Bachelet, Ido ^a   Munitz, Ariel ^a   Berent Maoz, Beata ^a   Mankuta, David ^b   Levi Schaffer, Francesca ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD300A ANTIBODY; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN SH2; SHIP 1 ENZYME; STEM CELL FACTOR; UNCLASSIFIED DRUG; CD300A PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; STEM CELL FACTOR RECEPTOR;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN ANAPHYLAXIS; ANAPHYLAXIS; ANIMAL; CAPPING PHENOMENON; DISEASE MODEL; IMMUNOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANAPHYLAXIS; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC CAPPING; MAST CELLS; MICE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 44449119063     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.9.6064     Document Type: Article

References (33)

1. Galli, S. J., J. Kalesnikoff, M. A. Grimbaldeston, A. M. Piliponsky, C. M. Williams, and M. Tsai. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23: 749-786. (Pubitemid 40563184)
2. Okayama, Y., and T. Kawakami. 2006. Development, migration, and survival of mast cells. Immunol. Res. 34: 97-115. (Pubitemid 43997964)
3. Mitsui, H., T. Furitsu, A. M. Dvorak, A. M. Irani, L. B. Schwartz, N. Inagaki, M. Takei, K. Ishizaka, K. M. Zsebo, and S. Gillis. 1993. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90: 735-739. (Pubitemid 23028940)
4. Irani, A. M., G. Nilsson, U. Miettinen, S. S. Craig, L. K. Ashman, T. Ishizaka, K. M. Zsebo, and L. B. Shwartz. 1992. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80: 3009-3021. (Pubitemid 23004504)
5. Valent, P., E. Spanblochl, W. R. Sperr, C. Sillaber, K. M. Zsebo, H. Agis, H. Strobl, K. Geissler, P. Bettelheim, and K. Lechner. 1992. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80: 2237-2245.
6. Saito, H., M. Ebisawa, N. Sakaguchi, T. Onda, Y. Iikura, M. Yanagida, H. Uzumaki, and T. Nakahata. 1995. Characterization of cord-blood-derived human mast cells cultured in the presence of Steel factor and interleukin-6. Int. Arch. Allergy Immunol. 107: 63-65.
7. Feldweg, A. M., D. S. Friend, J. S. Zhou, Y. Kanaoka, M. Daheshia, L. Li, K. F. Austen, and H. R. Katz. 2003. Gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur. J. Immunol. 33: 2262-2268. (Pubitemid 37010044)
8. Takagi, M., T. Nakahata, T. Kubo, M. Shiohara, K. Koike, A. Miyajima, K. Arai, S. Nishikawa, K. M. Zsebo, and A. Komiyama. 1992. Stimulation of mouse connective tissue-type mast cells by hemopoietic stem cell factor, a ligand for the c-kit receptor. J. Immunol. 148: 3446-3453.
9. Meininger, C. J., H. Yano, R. Rottapel, A. Bernstein, K. M. Zsebo, and B. R. Zetter. 1992. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79: 958-963.
10. Piliponsky, A. M., G. J. Gleich, A. Nagler, I. Bar, and F. Levi-Schaffer. 2003. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood 101: 1898-1904. (Pubitemid 36237591)
11. Welham, M. J., and J. W. Schrader. 1992. Steel factor-induced tyrosine phosphorylation in murine mast cells:common elements with IL-3-induced signal transduction pathways. J. Immunol. 149: 2772-2783.
12. Dvorak, A. M., R. A. Seder, W. E. Paul, E. S. Morgan, and S. J. Galli. 1994. Effects of interleukin-3 with or without the c-kit ligand, stem cell factor, on the survival and cytoplasmic granule formation of mouse basophils and mast cells in vitro. Am. J. Pathol. 144: 160-170. (Pubitemid 24158369)
13. Iwaki, S., C. Tkaczyk, A. B. Satterthwaite, K. Halcomb, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan. 2005. Btk plays a crucial role in the amplification of FcεRI-mediated mast cell activation by kit. J. Biol. Chem. 280: 40261-40270. (Pubitemid 41779164)
14. Zeng, S., Z. Xu, S. Lipkowitz, and J. B. Longley. 2005. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105: 226-232. (Pubitemid 40053087)
15. Tkaczyk, C., V. Horejsi, S. Iwaki, P. Draber, L. E. Samelson, A. B. Satterthwaite, D. H. Nahm, D. D. Metcalde, and A. M. Gilfillan. 2004. NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcεRI aggregation. Blood 104: 207-214. (Pubitemid 38879859)
16. Shivakrupa, R., A. Bernstein, N. Watring, and D. Linnekin. 2003. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 63: 4412-4419. (Pubitemid 36951012)
17. Piao, X., and A. Bernstein. 1996. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 87: 3117-3123. (Pubitemid 26115339)
18. Furitsu, T., T. Tsujimura, T. Tono, H. Ikeda, H. Kitayama, U. Koshimizu, H. Sugahara, J. H. Butterfield, L. K. Ashman, and Y. Kanayama. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92: 1736-1744. (Pubitemid 23304537)
19. Hirota, S., K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, et al. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580. (Pubitemid 28067289)
20. Malbec, O., W. H. Fridman, and M. Daeron. 1999. Negative regulation of c-kitmediated cell proliferation by FcγRIIB. J. Immunol. 162: 4424-4429. (Pubitemid 29314838)
21. Bachelet, I., A. Munitz, A. Moretta, L. Moretta, and F. Levi-Schaffer. 2005. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J. Immunol. 175: 7989-7995. (Pubitemid 41798360)
22. Bachelet, I., A. Munitz, and F. Levi-Schaffer. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J. Allergy Clin. Immunol. 117: 1314-1320. (Pubitemid 43795759)
23. Brennan, M., P. F. Davison, and H. Paulus. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229: 81-83. (Pubitemid 15018286)
24. Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science 290: 84-89.
25. Munitz, A., I. Bachelet, R. Eliashar, A. Moretta, L. Moretta, and F. Levi-Schaffer. 2006. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 107: 1996-2003. (Pubitemid 43289383)
26. Tam, S. W., S. Demissie, D. Thomas, and M. Daeron. 2004. A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 59: 772-780. (Pubitemid 38850354)
27. Zhu, D., C. L. Kepley, K. Zhang, T. Terada, T. Yamada, and A. Saxon. 2005. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat. Med. 11: 446-449. (Pubitemid 40562337)
28. Zhu, D., C. L. Kepley, M. Zhang, K. Zhang, and A. Saxon. 2002. A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat. Med. 8: 518-521. (Pubitemid 34546756)
29. Piao, X., R. Paulson, P. van der Geer, T. Pawson, and A. Bernstein. 1996. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA 93: 14665-14669. (Pubitemid 26419025)
30. Kepley, C. L., S. Taghavi, G. Mackay, D. Zhu, P. A. Morel, K. Zhang, J. J. Ryan, L. S. Satin, M. Zhang, P. P. Pandolfi, and A. Saxon. 2004. Coaggregation of FcγRII with FcεRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J. Biol. Chem. 279: 35139-35149. (Pubitemid 39100510)
31. Mertsching, E., L. Bafetti, H. Hess, S. Perper, K. Giza, L. C. Allen, E. Negrou, K. Hathaway, J. Hopp, J. Chung, et al. 2008. A mouse Fcγ-Fcε protein that inhibits mast cells through activation of FcγRIIB: SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J. Allergy Clin. Immunol. 121: 441-447.
32. Vitale, C., C. Romagnani, M. Falco, M. Ponte, M. Vitale, A. Moretta, A. Bacigalupo, L. Moretta, and M. C. Mingari. 1999. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc. Natl. Acad. Sci. USA 96: 15091-15096. (Pubitemid 30019770)
33. Cantoni, C., C. Bottino, R. Augugliaro, L. Morelli, E. Marcenaro, R. Castriconi, M. Vitale, D. Pende, S. Sivori, R. Millo, et al. 1999. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur. J. Immunol. 29: 3148-3159. (Pubitemid 29484205)